An immunological approach to acute myeloid leukaemia

Kaspers, 2012, Pediatric acute myeloid leukemia, Expert Rev Anticancer Ther, 12, 405, 10.1586/era.12.1 Faulk, 2014, Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia, Paediatr Drugs, 16, 213, 10.1007/s40272-014-0067-3 Vyas, 2015, Allogeneic hematopoietic cell transplantation for acute myeloid leukemia, Biol Blood Marrow Transplant, 21, 8, 10.1016/j.bbmt.2014.10.026 Lucchini, 2014, Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge, Expert Rev Hematol, 7, 291, 10.1586/17474086.2014.878644 Pui, 2011, Biology, risk stratification, and therapy of pediatric acute leukemias: an update, J Clin Oncol, 29, 551, 10.1200/JCO.2010.30.7405 Ribeiro, 2014, Advances in treatment of de-novo pediatric acute myeloid leukemia, Curr Opin Oncol, 26, 656, 10.1097/CCO.0000000000000136 Gruber, 2012, Molecular genetic of acute myeloid leukemia Karol, 2015, Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy, Br J Haematol, 168, 94, 10.1111/bjh.13107 Tasian, 2014, Molecular therapeutic approaches for pediatric acute myeloid leukemia, Front Oncol, 4, 55, 10.3389/fonc.2014.00055 Daigle, 2013, Potent inhibition of DOT1L as treatment of MLL-fusion leukemia, Blood, 122, 1017, 10.1182/blood-2013-04-497644 Vesely, 2013, Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy, Ann N Y Acad Sci, 1284, 1, 10.1111/nyas.12105 Tettamanti, 2013, Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors, Immunol Lett, 155, 43, 10.1016/j.imlet.2013.09.013 Locatelli, 2013, Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation, Immunol Lett, 155, 21, 10.1016/j.imlet.2013.09.027 Rettinger, 2012, The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells, Cytotherapy, 14, 91, 10.3109/14653249.2011.613931 Bader, 1999, Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children, Leukemia, 13, 2079, 10.1038/sj.leu.2401581 O’Hear, 2013, Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia, Cancer, 119, 4036, 10.1002/cncr.28334 Laszlo, 2014, Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML, Blood, 123, 554, 10.1182/blood-2013-09-527044 Ruggeri, 2006, Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation, Cytotherapy, 8, 554, 10.1080/14653240601078721 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Rubnitz, 2010, NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, J Clin Oncol, 28, 955, 10.1200/JCO.2009.24.4590 Moretta, 2014, Human natural killer cells: origin, receptors, function, and clinical applications, Int Arch Allergy Immunol, 164, 253, 10.1159/000365632 Locatelli, 2014, Natural killer cells in the treatment of high-risk acute leukaemia, Semin Immunol, 26, 173, 10.1016/j.smim.2014.02.004 Bennett, 1976, Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group, Br J Haematol, 33, 451, 10.1111/j.1365-2141.1976.tb03563.x Bene, 1995, Proposals for the immunological classification of acute leukemias European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, 9, 1783 Hasle, 2012, Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004, Blood, 120, 978, 10.1182/blood-2012-03-416701 Rubnitz, 2010, Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial, Lancet Oncol, 11, 543, 10.1016/S1470-2045(10)70090-5 Milosevic, 2012, Clinical significance of genetic aberrations in secondary acute myeloid leukemia, Am J Hematol, 87, 1010, 10.1002/ajh.23309 Lo-Coco, 2014, Understanding the molecular pathogenesis of acute promyelocytic leukemia, Best Pract Res Clin Haematol, 27, 3, 10.1016/j.beha.2014.04.006 Bierings, 2007, Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges, Curr Stem Cell Res Ther, 2, 53, 10.2174/157488807779317035 Davila, 2014, Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments, Paediatr Drugs, 16, 151, 10.1007/s40272-013-0048-y Nanbakhsh, 2014, c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis, Blood, 123, 3585, 10.1182/blood-2013-11-536219 Rohner, 2007, Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis, Leuk Res, 31, 1393, 10.1016/j.leukres.2007.02.020 Diermayr, 2008, NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities, Blood, 111, 1428, 10.1182/blood-2007-07-101311 Leung, 2014, NK cell transplantation as consolidation therapy in children with acute myeloid leukemia-results from a pilot study, Macs & More, 1, 15 Brehm, 2013, Highlights of the third international conference on immunotherapy in pediatric oncology, Pediatr Hematol Oncol, 30, 349, 10.3109/08880018.2013.802106